| --- |
| license: cc-by-nc-4.0 |
| language: |
| - en |
| tags: |
| - healthcare |
| - endocrinology |
| - osteoporosis |
| - bone-mineral-density |
| - dxa |
| - frax |
| - fracture-risk |
| - bisphosphonate |
| - denosumab |
| - synthetic-data |
| - ehr |
| - clinical |
| - fhir |
| pretty_name: "HC-END-007 Osteoporosis & Metabolic Bone Disease Synthetic Dataset (Sample)" |
| size_categories: |
| - n<1K |
| task_categories: |
| - tabular-classification |
| - tabular-regression |
| - survival-analysis |
| --- |
| |
| # HC-END-007 — Osteoporosis & Metabolic Bone Disease Synthetic Dataset (Sample) |
|
|
| **XpertSystems.ai · Synthetic Data Factory · Endocrinology Vertical** |
|
|
| A deeply trial-calibrated synthetic cohort of osteoporosis and metabolic bone disease patients |
| spanning DXA bone mineral density (lumbar/femoral neck/total hip), WHO classification, FRAX & |
| Garvan fracture risk, bone turnover markers (CTX, P1NP, osteocalcin, BSAP, sclerostin, RANKL/OPG), |
| treatment efficacy across nine drug classes, secondary osteoporosis workup, fall-risk & |
| neuromuscular assessment, and incident-fracture clinical outcomes. This repository contains a |
| **500-row, single-seed sample**. The full commercial product scales to 20,000+ patients with |
| 20-year longitudinal trajectories and CSV / Parquet / JSON / **FHIR R4** delivery. |
|
|
| Per-drug BMD gains and fracture risk ratios are **hard-anchored to landmark RCTs** (FIT, HORIZON, |
| FREEDOM, FRAME, ARCH) and applied directly — so drug-specific benchmarks reproduce the trial |
| literature precisely. |
|
|
| - **SKU:** HC-END-007 |
| - **Sample size:** 500 patients × 144 columns |
| - **License (sample):** CC-BY-NC-4.0 — commercial license available for the full product |
| - **Contact:** pradeep@xpertsystems.ai · https://xpertsystems.ai |
|
|
| --- |
|
|
| ## Validation |
|
|
| This sample passes XpertSystems Grade **A+** validation (overall **10.000 / 10**) with |
| deterministic reproduction across all six canonical seeds `[42, 7, 123, 2024, 99, 1]`. |
|
|
| Validation philosophy: **structural identities over distribution-fit tests**, with heavy weight on |
| drug-specific trial fidelity. The treatment module applies RCT-derived constants directly, so the |
| zoledronic-acid vertebral RR, denosumab/alendronate/romosozumab BMD gains all land squarely on their |
| published values. |
|
|
| ### Calibration anchors |
|
|
| | Metric | Sample value | Target range | Source | |
| |---|---|---|---| |
| | Osteoporosis prevalence | 61.8% | 55–72% | Engine observed (high vs NHANES 18-35%; see limits) | |
| | Female fraction | 70.8% | 65–78% | Osteoporosis female predominance ~72% | |
| | Vitamin D deficiency | 30.0% | 28–55% | US 50+ population ~30-55% | |
| | Treatment rate | 60.0% | 50–80% | Treatment among eligible ~55-75% | |
| | **Zoledronic acid vertebral RR** | **0.30** | **0.25–0.38** | HORIZON 2007 (~0.30) | |
| | **Denosumab spine BMD gain (3yr)** | **9.1%** | **7.5–11.5%** | FREEDOM 2009 (~9.2%) | |
| | **Alendronate spine BMD gain (3yr)** | **8.0%** | **6.5–10.5%** | FIT 1996 (~8%) | |
| | **Romosozumab spine BMD gain** | **13.5%** | **10–16.5%** | FRAME 2017 (~13.3%) | |
| | **T-score femoral neck in [-5,3.5]** | **100%** | **≥1.0** | DXA physiology bounds | |
| | **FRAX hip in [0.1,35]%** | **100%** | **≥1.0** | FRAX probability bounds | |
| | **BMD lumbar in [0.45,1.60]** | **100%** | **≥1.0** | DXA physiology bounds | |
| | **Column count** | **144** | **≥138** | Schema completeness (8 modules) | |
|
|
| --- |
|
|
| ## Schema highlights by module (144 columns) |
|
|
| **Demographics.** Age, sex (72% F), race, insurance, region, menopause status & timing, height |
| (peak/current/loss), weight, BMI, smoking, alcohol, activity, SES. |
|
|
| **Bone mineral density.** Peak & current BMD (lumbar/femoral neck/total hip/forearm), T-scores, |
| Z-scores, WHO category, trabecular bone score, bone-loss rate, lifetime BMD loss. |
|
|
| **Fracture risk.** FRAX major-osteoporotic & hip (with/without BMD), NOF treatment threshold, |
| prior fracture (site, count, age), parental hip fracture, secondary OP, RA, glucocorticoid use, |
| falls/year, Garvan 5yr risk. |
|
|
| **Secondary osteoporosis.** Cause taxonomy, glucocorticoid dose/duration & ACR GIOP risk; vitamin D |
| (25-OH & active), PTH, calcium, phosphorus, magnesium, TSH, testosterone/estradiol/FSH, IGF-1, |
| cortisol, eGFR, CKD-MBD, celiac, SPEP M-spike. |
|
|
| **Bone turnover markers.** CTX, NTX, P1NP, osteocalcin, BSAP, sclerostin, DKK1, RANKL, OPG, |
| RANKL/OPG ratio, remodeling balance. |
|
|
| **Treatment.** Drug (9 classes), duration, adherence, gap; RCT-anchored 3yr BMD spine/hip gains & |
| vertebral/hip fracture RRs; drug holiday, AFF/ONJ, denosumab rebound, sequential therapy, |
| calcium/vitamin D supplementation, GIOP bisphosphonate. |
|
|
| **Fall risk & neuromuscular.** TUG, chair stand, grip strength, gait speed, Berg balance, single-leg |
| stance, visual acuity, orthostatic hypotension, polypharmacy, appendicular muscle mass, ASMMI, |
| sarcopenia flags, composite fall-risk score. |
|
|
| **Clinical outcomes.** Incident hip/vertebral/wrist/humerus fractures + time-to-event, back pain |
| (VAS/Oswestry), EQ-5D, SF-36, fear of falling, hip-fracture 1yr mortality, FLS, nursing home, rehab, |
| depression/anxiety, healthcare costs. |
|
|
| **Coding.** ICD-10, LOINC; FHIR R4 DiagnosticReport bundle (full product). |
|
|
| --- |
|
|
| ## Files |
|
|
| - `hc_end_007_sample.csv` — 500-patient sample (144 columns) |
| - `generate_sample_dataset_hc_end_007.py` — reproducible generator + validation harness |
| - `validation_report.json` / `validation_report.md` — full scorecard |
| - `sweep_summary.json` — 6-seed determinism results |
|
|
| ## Loading |
|
|
| ```python |
| import pandas as pd |
| df = pd.read_csv("hc_end_007_sample.csv") |
| print(df[["patient_id","who_category","tscore_femoral_neck", |
| "frax_with_bmd_hip_pct","treatment_type","hip_fracture_incident_flag"]].head()) |
| ``` |
|
|
| ```python |
| from datasets import load_dataset |
| ds = load_dataset("csv", data_files="hc_end_007_sample.csv") |
| ``` |
|
|
| ## Use cases |
|
|
| - Fracture-risk prediction (FRAX/Garvan replication, BMD + clinical risk factors) |
| - Treatment-efficacy and comparative-effectiveness modeling across drug classes |
| - Time-to-event / survival analysis on incident hip & vertebral fractures |
| - Fall-risk and sarcopenia screening tooling |
| - Health-economics modeling (fracture episode costs, FLS impact) |
| - ML training where real osteoporosis EHR + DXA data is PHI-restricted |
|
|
| --- |
|
|
| ## Honest limitations & disclosed generator behavior |
|
|
| This engine has standout drug-level trial fidelity; the main caveat is cohort composition. |
|
|
| 1. **Osteoporosis prevalence runs high (~62%).** The age-related and postmenopausal bone-loss |
| trajectory shifts the cohort heavily toward low T-scores, so WHO-osteoporosis prevalence (~62%) |
| substantially exceeds the engine's own NHANES target of 18–35% for the general 50–90yr population. |
| Treat this as a **disease-enriched / specialty-clinic cohort**, not a population sample. The |
| median femoral-neck T-score is ~−1.9 (osteopenic-to-osteoporotic range). |
| 2. **Drug benchmarks are constants, not learned.** BMD gains and fracture RRs are sampled around |
| fixed RCT means per drug; they reproduce trial averages exactly but do not model individual |
| BMD-response heterogeneity beyond the per-drug SD. |
| 3. **Longitudinal is summary-level.** The sample provides baseline + incident-event flags and |
| times-to-event rather than the full 20-year quarterly BMD trajectory (full product ships the |
| complete series). |
| 4. **Some flags drawn independently.** Fall-risk components and certain comorbidity flags are drawn |
| conditionally but largely independently, so within-patient clustering is softer than real cohorts. |
|
|
| General caveat: cross-field correlations beyond those explicitly modeled may be weaker than in real |
| cohorts. **Not for clinical decision-making** — research/development use only. |
|
|
| --- |
|
|
| ## Commercial product comparison |
|
|
| | Capability | This sample | Full HC-END-007 product | |
| |---|---|---| |
| | Patients | 500 | 20,000+ (configurable) | |
| | Longitudinal | Baseline + incident events | 20-year quarterly BMD + fracture trajectory | |
| | Seeds / cohorts | 1 | Multi-seed, reproducible | |
| | Formats | CSV | CSV + Parquet + JSON + **FHIR R4 Bundle** | |
| | Cohort composition | Disease-enriched (~62% OP) | Tunable to population NHANES distribution | |
| | BMD response | Per-drug constant + SD | Individual response-heterogeneity model | |
| | License | CC-BY-NC-4.0 | Commercial | |
| | Support & SLA | — | Included | |
|
|
| Full product, custom cohorts, or other endocrinology SKUs: **pradeep@xpertsystems.ai** |
|
|
| --- |
|
|
| ## Citation |
|
|
| ```bibtex |
| @dataset{xpertsystems_hc_end_007_2026, |
| title = {HC-END-007: Osteoporosis & Metabolic Bone Disease Synthetic Dataset}, |
| author = {XpertSystems.ai}, |
| year = {2026}, |
| publisher = {XpertSystems.ai Synthetic Data Factory}, |
| url = {https://xpertsystems.ai}, |
| note = {Synthetic; CC-BY-NC-4.0 (sample). Drug efficacy hard-anchored to: FIT |
| (alendronate; Black et al. 1996); HORIZON (zoledronic acid; Black et al. |
| 2007, NEJM); FREEDOM (denosumab; Cummings et al. 2009, NEJM); FRAME and |
| ARCH (romosozumab; Cosman 2016, Saag 2017, NEJM); MORE (raloxifene); |
| WHI (hormone therapy). BMD reference: NHANES III (Looker et al. JBMR 1995). |
| Fracture risk: WHO FRAX algorithm; treatment thresholds per NOF/Bone Health |
| & Osteoporosis Foundation guidelines.} |
| } |
| ``` |
|
|
| *Synthetic data generated by XpertSystems.ai. Not derived from real patient records. |
| Not for clinical use.* |
|
|
